153 related articles for article (PubMed ID: 25564996)
1. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
[TBL] [Abstract][Full Text] [Related]
2. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.
Zombori T; Cserni G
Pathol Oncol Res; 2018 Apr; 24(2):259-267. PubMed ID: 28470571
[TBL] [Abstract][Full Text] [Related]
5. Comparison of GATA-3, Mammaglobin and GCDFP-15 Expression in Primary, Metastatic and Triple Negative Breast Carcinomas: An Indian Scenario.
Rao M; Khade S; Chaudhary R; Singh P; Yadav G; Elhence P; Nalwa A; Sharma R; Goel AD
Asian Pac J Cancer Prev; 2023 Feb; 24(2):509-515. PubMed ID: 36853299
[TBL] [Abstract][Full Text] [Related]
6. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
7. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
8. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
Kandalaft PL; Simon RA; Isacson C; Gown AM
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):609-614. PubMed ID: 26447897
[TBL] [Abstract][Full Text] [Related]
9. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
10. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
[TBL] [Abstract][Full Text] [Related]
11. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
13. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
14. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
[TBL] [Abstract][Full Text] [Related]
15. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
16. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
17. Markers of metastatic carcinoma of breast origin.
Gown AM; Fulton RS; Kandalaft PL
Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
[TBL] [Abstract][Full Text] [Related]
18. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
19. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
20. Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study.
El Hag MI; Hag AM; Ha JP; Michael CW
Pleura Peritoneum; 2017 Sep; 2(3):143-148. PubMed ID: 30911644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]